Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Times cited: 17
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The Lancet Oncology.
Times cited: 61
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?.
American Journal of Hematology.
Times cited: 18